Welcome to our dedicated page for Daxor Corporation news (Ticker: DXR), a resource for investors and traders seeking the latest updates and insights on Daxor Corporation stock.
Daxor Corporation Common Stock (DXR) represents a pioneering medical instrumentation and biotechnology company focused on the accurate measurement of blood volume. Daxor develops and markets the BVA-100 (Blood Volume Analyzer), which stands as the first FDA-cleared diagnostic tool capable of providing precise, objective quantification of blood volume status and composition compared to patient-specific norms. This technology is pivotal across a wide range of medical conditions.
The BVA-100 has revolutionized blood volume measurement, a practice that has historically been prone to lengthy and inaccurate testing processes. Traditional methods often took 4 to 8 hours and yielded inconsistent results. In contrast, the BVA-100 can deliver accurate and reliable measurements quickly, enhancing the capabilities of physicians who previously had to rely on less precise tests that measured blood thickness, often leading to misleading outcomes in critical medical situations.
Daxor Corporation, headquartered in New York, is at the forefront of medical technology and innovation. The company's recent achievements include the development of the next generation of Blood Volume Analyzer Systems, securing further research patents, and producing excellent clinical outcomes. These advancements are not only enhancing the quality of patient care but also strengthening the company's market position.
Financially, Daxor has shown robust growth, with unaudited revenue climbing 229.1% in the first two months of 2024 year-on-year. The company's strong start to 2024 is indicative of its commitment to innovation and excellence. Daxor is also actively engaged in strategic partnerships and investor relations, with Bret Shapiro serving as the Senior Managing Partner at CORE IR, ensuring transparent and effective communication with investors and stakeholders.
In addition to its technological developments, Daxor is also a notable presence in the medical community, participating in significant events such as the Premier Event for Cardiovascular Industry Leaders and Clinicians. The company's research and publications, such as those presented at the American College of Cardiology Scientific Sessions and in the American Heart Journal, underscore its dedication to advancing medical knowledge and practice.
Daxor (Nasdaq: DXR) has been awarded a $1.9 million two-year contract from the U.S. Air Force (USAF) to support the development of a next-generation point-of-care blood volume analyzer. This marks Daxor's third consecutive contract with the USAF, focusing on creating a novel fluorescent tracer and optical sensing technology for both military and civilian applications.
The funding comes through the USAF's Tactical Funding Increase (TACFI) Program of AFWERX, aimed at fostering innovation and rapid development of affordable technologies. Daxor's blood volume analysis (BVA) diagnostic is designed to improve decision-making in fluid resuscitation and blood transfusions, potentially enhancing patient survival rates and outcomes in combat casualty care and civilian settings.
Daxor (Nasdaq: DXR) announces the expansion of its blood volume analysis (BVA) technology to three new facilities. The company's ezBVA lab service, a CLIA-certified facility providing next-day results, is spearheading growth and broader market adoption. Recent sales wins include:
- A leading medical center in Georgia adopting ezBVA Lab service
- A North Carolina hospital purchasing a blood volume analyzer
- A top-rated Central Florida hospital implementing ezBVA Lab service
Daxor anticipates accelerated sales growth for the rest of the year. The company's Sr. VP of Commercialization and Customer Experience, Jean Oertel, emphasized that their diagnostic solution helps healthcare facilities enhance patient care while managing expenses. The increasing adoption of Daxor's BVA technology highlights its critical impact on advancing treatment effectiveness for fluid management.
Daxor (Nasdaq: DXR), the global leader in blood volume measurement technology, has been awarded a $550K matching-fund extension from the U.S. Defense Health Agency (DHA) to its Phase II SBIR contract. This funding will support the integration of hematocrit measurement into a future generation Blood Volume Analyzer (BVA).
The upgrade aims to streamline the BVA test by eliminating the need for third-party hematocrit testing devices. This marks Daxor's eighth SBIR award, demonstrating the DHA's ongoing commitment to advancing next-generation medical technologies. The company's goal is to make blood volume measurement faster and easier in various settings, from bedside to clinical testing labs and combat zones.
Daxor (Nasdaq: DXR) announced the expansion of its blood volume analysis (BVA) technology, including the launch of new BVA programs and the increased adoption of its ezBVA Lab service. This CLIA-certified facility provides next-day blood volume analysis results on-demand. Recent expansions include a regional referral center for Northeast Arkansas and Southeast Missouri, a 300-bed Covenant Health affiliate, and a leading South Texas teaching hospital and Level 1 trauma center. CEO Michael Feldschuh highlighted that strategic investments in sales and marketing are driving growth, with further developments expected in the year's second half.
Daxor (Nasdaq: DXR) will exhibit at the American Association of Heart Failure Nurses (AAHFN) 20th Annual Meeting from June 20-22, 2024, at the Rosen Shingle Creek Resort in Orlando, Florida. The company will showcase its BVA-100™ Guided-Care technology, which provides precise blood volume analysis to improve heart failure management. Daxor claims that this technology can reduce hospital stays, 30-day readmissions, and mortality rates, potentially transforming cardiovascular care. The event offers a platform for Daxor to present evidence supporting these benefits.
Daxor (Nasdaq: DXR) has appointed Dr. John L. Jefferies as Chief Medical Officer. Dr. Jefferies, an esteemed cardiologist with extensive clinical and commercial experience, will guide Daxor's strategic and clinical affairs. His role aims to accelerate the adoption of Daxor's diagnostic solutions in clinical practice, driving growth and collaboration with healthcare professionals. Dr. Jefferies brings a robust background in heart failure, cardiomyopathies, genetics, and AI, having published over 300 peer-reviewed manuscripts and served in numerous academic and leadership roles.
FAQ
What is the current stock price of Daxor Corporation (DXR)?
What is the market cap of Daxor Corporation (DXR)?
What does Daxor Corporation specialize in?
What is the BVA-100?
How has the BVA-100 improved blood volume measurement?
What are some recent achievements of Daxor Corporation?
How has Daxor performed financially in early 2024?
Who is the Investor Relations Contact at Daxor Corporation?
What kind of medical events does Daxor participate in?
Where has Daxor Corporation published its research findings?
What is the significance of the BVA-100 in medical practice?
Where is Daxor Corporation headquartered?
